Azora Therapeutics, Inc.

Azora Therapeutics, Inc.

NNASDAQ:AZR
3.81
USD
-0.28
(-6.85%)
Mar 11Next Earn
Azora Therapeutics, Inc.
NASDAQ:AZR
(Nasdaq Stock Market)

Recent

price

3.81

P/E

ratio

- -

div

yld

- -

ROIC.AI

No data availableFinancial data will appear here once available

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Revenue

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available
Business
Azora Therapeutics, Inc. is a biopharmaceutical company that develops therapies for immune-mediated inflammatory diseases. Its investigational oral drug, AT177, is being develop for inflammatory bowel diseases, with an initial focus on ulcerative colitis. The company was founded by Julie Saiki and Matthew Davidson which is headquartered in Los Angeles, CA.